Literature DB >> 7630043

Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.

K Umemura1, H Kawai, H Ishihara, M Nakashima.   

Abstract

This study investigated the roles of thromboxane A2 (TXA2), ADP and thrombin in middle cerebral artery (MCA) thrombosis in the rat. The rat MCA was occluded by a thrombus induced by the photochemical reaction of rose bengal by green light that causes endothelial damage followed by platelet adhesion, aggregation and formation of a platelet and fibrin-rich thrombus at the site of the photochemical reaction. Vapiprost, a specific TXA2-receptor antagonist; clopidogrel, which has the thienopyridine structure of ticlopidine and is a more potent inhibitor of ADP-induced platelet aggregation than ticlopidine; argatroban, a specific thrombin inhibitor; or heparin was administered intravenously before rose bengal injection. The MCA local blood flow was monitored by a laser Doppler flowmeter. The MCA was occluded by thrombus about 5 min after the initiation of the photochemical reaction. Vapiprost, clopidogrel and argatroban all significantly prolonged the time taken for the thrombotic occlusion of the MCA, but in this respect, heparin was ineffective. Our observations suggest that vapiprost and clopidogrel are useful antithrombotic agents against platelet and fibrin-rich thrombi. The effect of argatroban is attributable to inhibition of thrombin-induced platelet activation and fibrin generation. The thrombosis model described in this study is useful for understanding the mechanism(s) of thrombogenesis in the rat MCA and may be applied to other mammalian species.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7630043     DOI: 10.1254/jjp.67.253

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  6 in total

Review 1.  The role of secretory phospholipase A₂ in the central nervous system and neurological diseases.

Authors:  Tatsurou Yagami; Yasuhiro Yamamoto; Hiromi Koma
Journal:  Mol Neurobiol       Date:  2013-10-10       Impact factor: 5.590

2.  Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

3.  Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia.

Authors:  Tatsurou Yagami
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

4.  Anti-platelet therapy with clopidogrel prevents endothelial dysfunction and vascular remodeling in aortas from hypertensive rats.

Authors:  Fernanda R Giachini; Romulo Leite; David A Osmond; Victor V Lima; Edward W Inscho; R Clinton Webb; Rita C Tostes
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

5.  K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model.

Authors:  Hideo Yoshida; Yuka Ashikawa; Shinsuke Itoh; Takashi Nakagawa; Akimune Asanuma; Sohei Tanabe; Yoshihiro Inoue; Hiroyoshi Hidaka
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

6.  2-Amino-6-methyl-5-{5-[(naphthalen-2-yl-oxy)meth-yl]-1,3,4-oxadiazol-2-ylsulfan-yl}-4-(3-nitro-phen-yl)pyridine-3-carbonitrile.

Authors:  Hoong-Kun Fun; C S Chidan Kumar; Prescilla Patrao; A M A Khader; Balakrishna Kalluraya
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.